Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04467515
Recruitment Status : Not yet recruiting
First Posted : July 13, 2020
Last Update Posted : January 27, 2021
Sponsor:
Information provided by (Responsible Party):
Camel-IDS NV